Clinical observation of the treatment of ischemic heart failure with combination therapy esmolol and labetalol
10.3760/cma.j.issn.1008-6706.2016.09.013
- VernacularTitle:艾司洛尔、拉贝洛尔治疗缺血性心力衰竭的临床疗效比较
- Author:
Yue JIN
;
Fang FANG
- Publication Type:Journal Article
- Keywords:
Heart failure;
Esmolol;
Labetalol
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(9):1329-1332
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of intravenous injection of esmolol,labetalol and their combination in the treatment of ischemic heart failure (ICD).Methods 80 patients with ICD were randomly divided into treat-ment group 1 (20 cases),treatment group 2(20 cases),treatment group 3 (20 cases)and control group(20 cases). The treatment group 1 was intravenously given esmolol on the basis of routine treatment.the treatment group 2 was intravenously given labetalol on the basis of the conventional treatment.the treatment group 3 was intravenously given esmolol and labetalol on the basis of routine treatment.The control group only received routine treatment.The thera-peutic effects of the four groups were observed and compared,and the changes of blood pressure,heart rate,walking distance and ultrasonic electrocardiogram before and after treatment were recorded.Results In the treatment group 1,3 cases with marked effect,effective in 14 cases,the total effective rate was 85%.In the treatment group 2,2 cases with marked effect,effective in 14 cases,the total effective rate was 80% cases.In the treatment group 3,4 cases with marked effect,effective in 15 cases,the total effective rate was 95%.In the control group,1 case with marked effect, effective in 10 cases,the total effective rate was 55%.The treatment effect of the treatment group 1,2,3 was better than the control group (P <0.05).The treatment effect of the treatment group 1,2 was significantly lower than the treatment group 3 (P <0.05).The treatment effect between the treatment group 1 and group 2 had no significant difference (P >0.05 ).After treatment,6 min walking distance and LVEF,FS,SV and other indicators of cardiac function were significantly improved in the four groups (P <0.05 ).The four groups had no significant adverse reactions such as nausea,vomiting,liver and renal function after treatment.Conclusion Intravenous injection of esmolol,labetalol or both drugs for treatment of ICD can improve cardiac function,with no adverse reaction,and it is safe and reliable,worthy of clinical application.
